中经记者 陈婷 赵毅 深圳报道 9月24日，港股上市公司百奥赛图（2315.HK）科创板IPO过会，两天后，该公司向中国证监会提交注册 申请，距离实现"H+A"两地上市就差临门一脚。 根据注册稿，百奥赛图主要从事基于小鼠模型的药物发现及临床前CRO（医药合同研究）服务、抗体 药物研发业务。两年多前，百奥赛图冲刺科创板上市，彼时其还陷于亏损之中，相关财务资料在IPO期 间多次失效。 此次在科创板申请上市过程中，有关百奥赛图"技术先进性"的问询贯穿始终。第二轮问询期间，上交所 要求保荐机构对百奥赛图是否符合《首次公开发行注册管理办法》第三条规定的"拥有关键核心技术， 科技创新能力突出，主要依靠核心技术开展生产经营"的科创板定位要求发表明确意见。与此同时，百 奥赛图研发费用大幅下降、研发人员从高峰期超600人减至403人、核心技术CRISPR/EGE已于10年前在 国内申请专利但尚未获授权等现象引起市场高度关注。 近日，百奥赛图方面在接受《中国经营报》记者采访时表示，2022年至2024年，公司研发投入逐年下 降，主要是因为大规模战略研发阶段结束。公司研发体系保持完整，未来将根据业务发展阶段、盈利及 现金流预测合理 ...

（编辑 袁冠琳） 证券日报网讯 蓝帆医疗10月9日在互动平台回答投资者提问时表示，公司参股投资的同心医疗于2025年 6月底完成上市前融资，2025年7月已重启IPO。随着科创板第五套标准重启，其上市进程有望加速。当 然，其上市进程也受宏观经济、监管政策、市场环境及企业自身经营状况等多重因素影响，存在不确定 性。公司将持续关注同心医疗上市进度，具体以同心医疗公司公开披露信息为准。 ...

新光光电上市募集资金总额为9.52亿元，募集资金净额为8.65亿元。新光光电于2019年7月16日披露的招 股说明书显示，公司拟募集资金8.76亿元，分别用于光机电一体化产品批产线升级改造及精密光机零件 制造项目、睿光航天光电设备研发生产项目、研发中心建设项目、补充流动资金。 新光光电的发行费用共计8704.16万元，其中中信建投作为保荐机构和主承销商获得保荐、承销费用 7618.00万元。 中国经济网北京9月29日讯新光光电(688011.SH)晚间发布关于重大事项的公告，公司近日收到嵩县监察 委员会签发的关于对公司控股股东、实际控制人、董事长、总经理康为民的《立案通知书》和《留置通 知书》，康为民被实施留置措施。 公司于2025年9月28日召开董事会临时会议，除公司董事长康为民未能出席外，其他董事全部出席。会 议形成如下决议：1、根据《公司章程》第一百一十五条，在康为民留置期间，由公司副董事长王玉伟 代为履行公司董事长及法定代表人职责，以及代为履行公司董事会相关委员会成员的职责；2、在康为 民留置期间，由公司副总经理曲波代为履行公司总经理职责。 新光光电表示，截至公告披露日，公司控制权未发生变化，董事会运 ...

联席主承销商：中信建投证券股份有限公司 ２０２５年９月２３日 ■ 发行人：武汉禾元生物科技股份有限公司 保荐人（联席主承销商）：国泰海通证券股份有限公司 武汉禾元生物科技股份有限公司（以下简称"禾元生物"、"发行人"或"公司"）首次公开发行股票并在科 创板上市的申请已经上海证券交易所（以下简称"上交所"）科创板上市委员会审议通过，并已经中国证 券监督管理委员会（以下简称"中国证监会"）证监许可〔２０２５〕１４６８号文同意注册。《武汉禾 元生物科技股份有限公司首次公开发行股票并在科创板上市招股意向书》及附录在上海证券交易所网站 （ｈｔｔｐ：／／ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ／）和符合中国证监会规定条件网站（中证网，网址 ｗｗｗ．ｃｓ．ｃｏｍ．ｃｎ；中国证券网，网址ｗｗｗ．ｃｎｓｔｏｃｋ．ｃｏｍ；证券时报网，网 址ｗｗｗ．ｓｔｃｎ．ｃｏｍ；证券日报网，网址ｗｗｗ．ｚｑｒｂ．ｃｎ）披露，并置备于发行人、 本次发行保荐人（联席主承销商）国泰海通证券股份有限公司和联席主承销商中信建投证券股份有限公 司的住所，供公众查阅。 敬请投资者重点关注本次发行流程、网上网下申购及缴款、弃购股份处理等方面，并认真阅读同日披露 于上海证 ...

Core Viewpoint - The Hong Kong Stock Exchange has issued a disciplinary action against Shanghai Henlius Biotech, Inc. and its former CEO, Dr. Liu Shigao, for compliance failures related to the company's IPO in 2019 [2][4]. Group 1: Disciplinary Action - The Hong Kong Stock Exchange criticized Henlius and Dr. Liu for failing to adhere to compliance standards, mandating Dr. Liu to complete 26 hours of training on regulatory and listing rule compliance before being eligible for reappointment as a director [4]. - The disciplinary action stems from a management agreement signed by the former CFO on the company's IPO day, which involved a $117 million investment from IPO proceeds that did not align with the stated use of funds in the prospectus [4]. Group 2: Company Performance - Henlius reported a revenue of 2.82 billion yuan for the first half of the year, a 2.7% increase year-on-year, with a net profit of 390 million yuan [8]. - For 2024, the company achieved a revenue of 5.724 billion yuan, reflecting a 6.1% year-on-year growth, and a net profit of 821 million yuan, marking a 50.3% increase [9]. Group 3: Product Portfolio and Market Presence - Henlius has six products approved for sale, covering 25 indications, including major monoclonal antibodies, with four products approved in various overseas markets [9]. - The company has a robust pipeline with 50 molecules and 10 research platforms, encompassing a diverse range of drug formats [9]. Group 4: Corporate History and Relationships - Dr. Liu co-founded Henlius in partnership with Dr. Jiang Weidong after returning to China in 2008, and he maintained a close relationship with the company even after his departure [6]. - In June 2023, Henlius and Dr. Liu's new venture, HanchorBio, announced a collaboration that includes a $10 million upfront payment and potential milestone payments totaling $192 million [6]. Group 5: Privatization Attempt - In June 2024, Fosun Pharma announced plans to privatize Henlius at specific share prices, citing underperformance in stock price and trading volume since the IPO [10]. - However, the privatization attempt was declared unsuccessful in January 2023 [11].

Core Viewpoint - The investigation of senior executives at "China's first domestic database stock" raises concerns about potential bribery and significant violations during the company's listing on the Sci-Tech Innovation Board [2][8] Group 1: Investigation Details - On August 21, 2023, the company announced that its board member and senior vice president Chen Wen is under investigation by the Hubei Provincial Supervisory Committee [2] - On August 19, 2023, the company disclosed that its board member and general manager Pi Yu is also under investigation and has been detained [2] - Both executives have extensive sales backgrounds, with Pi Yu having served in various roles at the company since 2010 and Chen Wen holding similar positions since 2002 [3][7] Group 2: Previous Bribery Allegations - Historical records indicate that the company has faced bribery allegations, with a case involving a payment made to a government official to expedite project payments [6][7] - In 2013, a payment of 50,000 yuan was made to a government official to facilitate the settlement of a project worth 7.26 million yuan [6] Group 3: Company Profile and Financials - The company is a leading developer of database products in China, providing services to large and medium-sized enterprises, government agencies, and institutions [4] - The company's accounts receivable growth significantly outpaces revenue growth, with accounts receivable increasing by 179.73% while revenue grew by 31.49% in the 2024 reporting period [4] Group 4: Listing Concerns - The company went public on the Sci-Tech Innovation Board on June 12, 2024, issuing 19 million shares at a price of 86.96 yuan per share [8] - The investigation of the executives raises questions about potential major violations that could affect the legitimacy of the company's listing [8][9]

Core Insights - Tianjin Feixuan Technology Co., Ltd. (Feixuan Technology) has disclosed its progress report on the guidance for its Sci-Tech Innovation Board listing, indicating that the company's performance has not met expectations due to various adverse factors, including macroeconomic conditions and industry competition [2] - Although the company's revenue and profit levels have shown some recovery, they still fall short of the requirements for listing, and the company faces risks related to operational performance fluctuations [2] Company Overview - Feixuan Technology was established in 2012 with a registered capital of 375 million yuan, specializing in providing overall solutions for magnetic levitation high-speed rotating machinery [2] - The company operates under two brands: Feixuan and Yisheng, with Hong Shenping serving as the chairman, general manager, and actual controller [2] Guidance Team - The report discloses the list of individuals receiving guidance, which includes all company directors (including independent directors), supervisors, senior management, and representatives of shareholders holding more than 5% of shares, totaling 14 individuals [2][3] - Key personnel include Hong Jiaping (Chairman, General Manager, Actual Controller), Sha Honglei (Director, Deputy General Manager), and Li Donghui (Director, Board Secretary, Chief Financial Officer) [3]

Group 1 - The core viewpoint of the article indicates that Tianjin Feixuan Technology Co., Ltd. is facing challenges in meeting the listing conditions on the Sci-Tech Innovation Board due to various adverse factors, including macroeconomic conditions and industry competition [1] - The report reveals that although the company's revenue and profit levels have shown some recovery, they still fall short of the requirements for listing [1] - The company is experiencing operational performance fluctuations and needs to further improve its business performance in the future [1] Group 2 - Feixuan Technology was established in 2012 with a registered capital of 375 million yuan and specializes in providing overall solutions for magnetic levitation high-speed rotating machinery [3] - The company operates under two main brands: Feixuan and Yisheng [3] - The chairman, general manager, and actual controller of the company is Hong Shenping, who holds approximately 50.5% of the shares [3]

Core Viewpoint - Guangzhou Bibet Pharmaceutical Co., Ltd. has received approval for its IPO on the Sci-Tech Innovation Board after a lengthy registration process, despite reporting no revenue and significant losses over the past three years [2][5]. Group 1: Company Overview - Bibet was established in January 2012 and transitioned to a joint-stock company in December 2021, with a registered capital of approximately 360 million yuan [4]. - The company has one wholly-owned subsidiary and two branch offices, employing a total of 154 staff as of the end of 2024 [4]. Group 2: Financial Performance - The company reported no revenue for the three years from 2022 to 2024, with cumulative losses amounting to 417 million yuan [7]. - The net profit for 2024 is projected at -56 million yuan, a significant reduction from the -172.76 million yuan loss in 2023 [8]. Group 3: Product Development - Bibet focuses on innovative drug development, particularly in oncology, autoimmune diseases, and metabolic disorders, with its core product BEBT-908 already approved for market [5]. - The company has multiple products in various stages of clinical trials, including BEBT-209 in Phase III and BEBT-109 approved for Phase III trials [5]. Group 4: Shareholding Structure - The company has no controlling shareholder, with Qian Changgeng as the actual controller, holding 15.28% of shares directly and controlling an additional 8.59% through a partnership [6]. - Qian Changgeng, the founder, has been instrumental in the company's board composition and holds several key patents [6]. Group 5: IPO and Fundraising - The company plans to raise over 2 billion yuan through its IPO, with 500 million yuan allocated for working capital and the remainder for new drug development and establishing a research center [12]. - The total investment for the new drug development project is estimated at approximately 949.12 million yuan [12]. Group 6: Compliance and Market Position - Bibet meets the Sci-Tech Innovation Board's listing criteria, including having a core product approved for clinical trials and demonstrating significant technological advantages [9][11]. - The company has invested heavily in R&D, with cumulative expenditures exceeding 80 million yuan over the past three years, and a high percentage of its workforce dedicated to R&D [10].

中国经济网北京8月7日讯据上交所网站消息，上海证券交易所上市审核委员会定于2025年8月14日召开 2025年第31次上市审核委员会审议会议，届时将审议西安奕斯伟材料科技股份有限公司(以下简称"西安 奕材")的首发事项。 西安奕材拟在上交所科创板募集资金490,000.00万元，用于西安奕斯伟硅产业基地二期项目。 截至招股说明书签署日，奕斯伟集团直接持有公司12.73%的股份，为公司第一大股东，奕斯伟集团及 其一致行动人奕斯欣盛、奕斯欣诚、奕斯欣合、宁波奕芯和重庆奕芯直接控制公司25.68%的股份。因 此，奕斯伟集团为公司控股股东。奕明科技持有奕斯伟集团52.40%的股权，为公司间接控股股东。 公司的实际控制人为王东升、米鹏、杨新元和刘还平四人。2019年11月，奕斯伟集团部分股东将表决权 委托于王东升。基于前述表决权委托，王东升与米鹏、杨新元和刘还平三位奕斯伟集团的管理团队股东 于2019年12月签署《一致行动协议》。截至招股说明书签署日，四人直接和间接控制公司控股股东奕斯 伟集团合计67.92%的股权。 西安奕材的保荐机构(主承销商)为中信证券股份有限公司，保荐代表人为张欢、陈泽。 ...